# Efficacy Trial of a Commercial EV71 Vaccine

> **NCT03903926** · PHASE4 · COMPLETED · sponsor: **Sinovac Biotech Co., Ltd** · enrollment: 15500 (actual)

## Conditions studied

- Hand, Foot and Mouth Disease

## Interventions

- **BIOLOGICAL:** 5000 volunteers (6-35 months)-EV71 vaccine

## Key facts

- **NCT ID:** NCT03903926
- **Lead sponsor:** Sinovac Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-26
- **Primary completion:** 2020-06-30
- **Final completion:** 2020-10-30
- **Target enrollment:** 15500 (ACTUAL)
- **Last updated:** 2021-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03903926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03903926, "Efficacy Trial of a Commercial EV71 Vaccine". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03903926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*